Obsidian Therapeutics (NASDAQ:OBX) Stock Short Interest Report for September

Obsidian Therapeutics (NASDAQ:OBX) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 884,528 shares, a growth of 249.5% from the September 15th total of 253,084 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily volume of 1,019,181 shares, the days-to-cover ratio is currently 0.9 days.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Lifesci Capital started coverage on shares of Obsidian Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price objective for the company. William Blair raised shares of Obsidian Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Leerink Partners initiated coverage on shares of Obsidian Therapeutics in a research report on Tuesday, September 22nd. They set an “outperform” rating and a $32.00 target price on the stock. Weiss Ratings assumed coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Finally, Wall Street Zen raised Obsidian Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Obsidian Therapeutics Trading Down 1.6%

Shares of NASDAQ OBX traded down $0.21 during trading hours on Monday, hitting $12.79. 420,010 shares of the stock were exchanged, compared to its average volume of 734,368. Obsidian Therapeutics has a one year low of $12.07 and a one year high of $49.97. The business’s 50 day moving average is $18.14.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.

The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.

Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information.